BMO Capital Reiterates Outperform on Terns Pharma, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has reiterated an Outperform rating on Terns Pharma (NASDAQ:TERN) and maintained a price target of $19.
August 06, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Etzer Darout has reiterated an Outperform rating on Terns Pharma and maintained a price target of $19.
The reiteration of an Outperform rating and a maintained price target of $19 by BMO Capital is a positive signal for Terns Pharma. This could boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100